PET imaging may better predict long-term benefits and guide discontinuation of therapy compared to standard contrast CT for patients with metastatic melanoma, according to findings presented Monday, June 4, at the 2018 American Society of Clinical Oncology (ASCo) annual meeting in Chicago. {read more here}

SNMMI, the Mayo Clinic, Washington University School of Medicine in St. Louis, and Memorial Sloan Kettering Cancer Center have jointly filed comments with the U.S. Food and Drug Administration (FDA) with recommendations that would make it easier for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to tolerate and, therefore, benefit from lutetium-177 (¹⁷⁷Lu) DOTATATE therapy. {read more here}

The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,¹ have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium-177-Dotatate (177-Lu-Dotatate; Lutathera) led to markedly longer progression-free survival and significantly higher response rates vs the control arm. {read more here}

It might not be the majority of hospitals’ standard routine, but including a patient’s head during routine body imaging with FDG PET/MRI could detect far more brain abnormalities than traditional practice, according to research published in the American Journal of Roentgenology. {read more here}